Reporting recommendations for tumor marker prognostic studies (REMARK)

Journal of the National Cancer Institute

Volumn 97, Issue 16, 2005, Pages 1180-1184

  McShane, Lisa M ^a   Altman, Douglas G ^b   Sauerbrei, Willi ^c   Taube, Sheila E ^a   Gion, Massimo ^d   Clark, Gary M ^e   Costa, Jose ^f   Di Leo, Angelo ^g   Mayer, Robert J ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WOLFSON COLLEGE   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Ospedale Civile   (Italy)

^e OSI PHARMACEUTICALS INC   (United States)

^f YALE CANCER CENTER   (United States)

^g HOSPITAL OF PRATO   (Italy)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; BIOASSAY; CANCER RESEARCH; HEALTH CARE ORGANIZATION; HUMAN; HYPOTHESIS; INFORMATION DISSEMINATION; INFORMATION PROCESSING; MALIGNANT NEOPLASTIC DISEASE; MATERIALS HANDLING; MEDICAL DECISION MAKING; METHODOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; STATISTICAL ANALYSIS; MEDICAL RESEARCH; NEOPLASM; STANDARD;

BIOMEDICAL RESEARCH; HUMANS; INFORMATION DISSEMINATION; NEOPLASMS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 23844534811     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji237     Document Type: Article

References (42)

1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
2. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. for the American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
3. Schilsky RL and Taube SE. Introduction: Tumor markers as clinical cancer tests - are we there yet? Semin Oncol 2002;29:211-2.
4. McGuire WL. Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 1991;83:154-5.
5. Fielding LP, Fenoglio-Preiser CM, and Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992;70:2367-77.
6. Burke HB, Henson DE. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72:3131-5.
7. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10.
8. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-19.
9. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.
10. Gasparini G. Prognostic variables in node-negative and node-positive breast cancer. Breast Cancer Res Treat 1998;52:321-31.
11. Hall PA, Going JJ. Predicting the future: A critical appraisal of cancer prognosis studies. Histopathology 1999;35:489-94.
12. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 2002;12:1-6.
13. Thor AD, Liu S, Moore DH II, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999;17:470-7.
14. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, DiLeo A, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000;113:675-82.
15. McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, et al., and the National Cancer Institute Bladder Tumor Marker Network. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 2000;6:1854-64.
16. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 2002;94:852-4.
17. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7.
18. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72: 511-8.
19. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002;122:1037-57.
20. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235:10-26.
21. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: Current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191-8.
22. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 2003;39:19-30.
23. Burton A, Altman DG. Missing covariate data within cancer prognostic studies: A review of current reporting and proposed guidelines. Br J Cancer 2004;91:4-8.
24. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 2004;22:529-36.
25. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004;10:4-12.
26. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998;52: 289-303.
27. Gion M, Boracchi P, Biganzoli E, Daidone MG. A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers). Int J Biol Markers 1999;14:123-33.
28. Altman DG. Systematic reviews of evaluations of prognostic variables. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. 2nd ed. London (UK): BMJ Books; 2001. p. 228-47.
29. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
30. McShane LM, Simon R. Statistical methods for the analysis of prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RV, O'Sullivan B, Sobin LH, Wittekind Ch, editors. Prognostic factors in cancer. 2nd ed. New York (NY): Wiley-Liss; 2001. p. 37-48.
31. Simon R. Evaluating prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RV, O'Sullivan B, Sobin LH, Wittekind Ch, editors. Prognostic factors in cancer. 2nd ed. New York (NY): Wiley-Liss; 2001. p. 49-56.
32. Biganzoli E, Boracchi P, Marubini E. Biostatistics and tumor marker studies in breast cancer: Design, analysis and interpretation issues. Int J Biol Markers 2003;18:40-8.
33. Schumacher M, Hollander N, Schwarzer G, Sauerbrei W. Prognostic factor studies. In: Crowley J, editor. Handbook of statistics in clinical oncology. New York (NY): CRC Press; 2005. p. 307-51.
34. Moher D, Schulz KF, Altman D for the CONSORT Group. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
35. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6.
36. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
37. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 1992;22:197-206.
38. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup D for the QUOROM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Lancet 1999;354:1896-900.
39. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
40. Hammond ME, Taube SE. Issues and barriers to development of clinically useful tumor markers: A development pathway proposal. Semin Oncol 2002;29:213-21.
41. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001;134:663-94.
42. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Clin Chem 2003;49:7-18.